Impact of the COVID-19 Pandemic on Dermatology Practice Worldwide: Results of a Survey Promoted by the International Dermoscopy Society (IDS)

Claudio Conforti¹, Aimilios Lallas², Giuseppe Argenziano³, Caterina Dianzani⁴, Nicola Di Meo⁴, Roberta Giuffrida⁵, Harald Kittler⁶, Josep Malvehy⁷, Ashfaq A. Marghoob⁸, H. Peter Soyer⁹,¹⁰ Iris Zalaudek¹

¹ Department of Dermatology and Venereology, Dermatology Clinic, Maggiore Hospital, University of Trieste, Italy
² First Dermatology Department, Aristotle University of Thessaloniki, Greece
³ Department of Dermatology, University of Campania, Luigi Vanvitelli, Naples, Italy
⁴ Dermatology Section, Plastic and Reconstructive Surgery Unit, Campus Biomedico University, Rome, Italy
⁵ Department of Clinical and Experimental Medicine, Dermatology, University of Messina, Italy
⁶ Department of Dermatology, Medical University of Vienna, Austria
⁷ Dermatology Department, Melanoma Unit, Hospital Clinic, University of Barcelona, Spain
⁸ Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
⁹ The University of Queensland Diamantina Institute, The University of Queensland, Dermatology Research Centre, Brisbane, QLD, Australia
¹⁰ Department of Dermatology, Princess Alexandra Hospital, Brisbane, QLD Australia

Key words: COVID-19, teledermatology, survey, SARS-CoV-2, dermatology

Citation: Conforti C, Lallas A, Argenziano G, Dianzani C, Di Meo N, Giuffrida R, Kittler H, Malvehy J, Marghoob AA, Soyer HP, Zalaudek I. Impact of the COVID-19 pandemic on dermatology practice worldwide: results of a survey promoted by the International Dermoscopy Society. Dermatol Pract Concept. 2021;11(1):e2021153. DOI: https://doi.org/10.5826/dpc.1101a153

Accepted: September 27, 2020; Published: January 29, 2021

Copyright: ©2021 Conforti et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License BY-NC-4.0, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: None.

Competing interests: The authors have no conflicts of interest to disclose.

Authorship: All authors have contributed significantly to this publication.

Corresponding author: Claudio Conforti, MD, Dermatology Clinic, University of Trieste, Piazza dell’Ospitale 1, Trieste, 34125, Italy. Email: claudioconforti@yahoo.com

ABSTRACT

Introduction: The International Dermoscopy Society (IDS) conducted an online survey to investigate the impact of coronavirus disease 2019 (COVID-19) outbreak on the daily practice of dermatologists working with skin cancer patients, to collect data regarding the frequency of skin manifestations noticed by the members, and to obtain information about the use of teledermatology during the pandemic.

Methods: All IDS members were asked to fill in a questionnaire, sent by email. A questionnaire available in English was sent to all IDS members (≈16,000 members) by email. The questionnaire was anonymous, with a compiling time of less than 5 minutes. The survey was open for 30 days (from April 24, 2020 to May 24, 2020) and it could only be filled out once.
Introduction

On December 2019, a novel coronavirus, SARS-CoV-2, started the outbreak of coronavirus disease 2019 (COVID-19) that rapidly spread worldwide and caused thousands of infections and deaths. Because of the enormous burden, it was officially recognized as a pandemic by the World Health Organization on March 11, 2020 [1,2].

To cope with this worldwide emergency, hospitals have been rapidly reorganized to increase the number of intensive or sub-intensive care units, and other departments have been closed or readapted to focus only on urgent health care services, including non-deferrable dermatological visits. Moreover, telemedicine services were rapidly implemented mostly to guarantee the remote management of patients requiring continuous treatment [3,4]. An increased number of unusual dermatological manifestations were reported, initially among children and later in adults, which raised the suspicion of a possible correlation between coronavirus disease 2019 (COVID-19) and dermatological eruptions [5-7]. To date, no skin manifestation appears pathognomonic of COVID-19, as many of the described skin rashes can be seen during the course of other viral infections. For this reason, the International Dermoscopy Society (IDS) conducted an online survey with 3 aims: first, to investigate the impact of the COVID-19 outbreak on the daily practice of dermatologists working with skin cancer patients; second, to collect data regarding the frequency of skin manifestations noticed by its members; and third, to obtain information about the use of teledermatology during the pandemic.

Methods

A questionnaire was sent to all IDS members (16,000 members) by email. It consisted of 24 questions, 4 regarding the respondent's personal data, 7 on the organization of the dermatology department/clinic and on possible contact with COVID-19 positive patients, 9 on cutaneous manifestations in COVID-19 patients, and 4 on teledermatology and diagnosis during the pandemic.

Results:

Overall, 678 dermatologists responded to the questionnaire; 334 members stated that there has been a reduction of more than 75% in daily work activity during the pandemic, 265 dermatologists worked fewer days per week, and 118 experienced teledermatology for the first time. Acrodermatitis was the most frequently observed skin manifestation (n = 80) followed by urticarial rash (n = 69), morbilliform rash (n = 53) and purpuric manifestation (n = 40). In regard to the role of teledermatology, 565 dermatologists reported an increased number of teleconsultations, and the number of melanomas diagnosed during the pandemic was practically 0 for 385 (56.78%) of respondents.

Conclusion: This survey highlights that the outbreak had a negative impact on most dermatology services, with a significant reduction in consultation time spent for chronic patients, and an increased risk of missed melanoma and nonmelanoma skin cancer (NMSC) diagnosis. Moreover, our study confirms earlier findings of a wide range of skin manifestations associated with COVID-19.

Table 1. Characteristics of the 678 Members Who Completed the International Dermoscopy Society Survey

| Sex          |          |
|--------------|----------|
| Men          | 260 (38.35%) |
| Woman        | 418 (61.65%) |

| Mean age     | 47.7 (range 26-76) |

| Workplace (more than one answer possible) | |
|------------------------------------------|----------|
| University hospital                       | 232 (27.79%) |
| Private hospital                          | 67 (8.02%) |
| Private clinic                            | 264 (31.62%) |
| Public clinic                             | 127 (15.20%) |
| Outpatient clinic                         | 145 (17.37%) |
to focus on dermatological emergencies. To prevent febrile patients from entering the hospital, a dedicated triage was created in most of the centers (376/678; 55.46%) where dermatologists worked to measure body temperature and to equip patients with surgical masks (Table 2). To cope with the emergency, the majority of participants 265/678 (39.08%) stated that they worked fewer days per week at the dermatology departments to ensure urgent or non-renewable visits, 9/678

| N=678 | %     | Count |
|-------|-------|-------|
| Did you reduce your daily work activity since the beginning of the pandemic? |       |       |
| Yes, about 25% | 10.17% | 69    |
| Yes, about 50% | 18.44% | 125   |
| Yes, about 75% | 18.44% | 125   |
| Yes, more than 75% | 49.26% | 334   |
| No | 3.69% | 25    |
| Was there a dedicated triage for dermatological outpatients? |       |       |
| Yes, patients wear the mask and temperature was measured | 35.40% | 240   |
| Yes, without measuring the temperature | 20.06% | 136   |
| No, but patients wear the mask | 22.42% | 152   |
| None of the above | 22.12% | 150   |
| Did you work in COVID-19 dedicated departments? |       |       |
| Yes, not as dermatologist | 11.21% | 76    |
| No, I worked only using teledermatology | 27.73% | 188   |
| No, I worked every day as dermatologist | 21.98% | 149   |
| No, I worked few days per week in the dermatology department | 39.08% | 265   |
| Did you come into contact with COVID-19 positive patients? |       |       |
| Yes, I got in contact with confirmed case | 12.83% | 87    |
| Yes, I got in contact with patient confirmed case | 18.29% | 124   |
| No | 68.88% | 467   |
| Did you test positive for COVID-19? |       |       |
| Yes | 3.54% | 24    |
| Not | 43.81% | 297   |
| A test has not been performed | 52.65% | 357   |
| Did you see COVID-19 patients with skin manifestations? |       |       |
| Yes | 16.37% | 111   |
| No | 83.63% | 567   |

Table 2. Answers from the International Dermoscopy Society Survey Questions

| N=678 | %     | Count |
|-------|-------|-------|
| What was the average age of the patient(s)? (more than 1 answer possible) |       |       |
| 1-20 | 31.44% | 58    |
| 20-40 | 29.34% | 54    |
| 40-60 | 22.82% | 42    |
| >60 | 16.40% | 30    |
| The number of teleconsultations you were asked to do during COVID-19 pandemic was |       |       |
| As usual | 16.67% | 113   |
| Increased a little bit | 23.30% | 158   |
| Doubled | 16.96% | 115   |
| Multiplied | 43.07% | 292   |
| The number of melanomas you diagnosed (including by teleconsultations) during the pandemic was |       |       |
| The same as usual | 15.93% | 108   |
| A little bit lower than usual | 9.89% | 67    |
| Almost half of the usual | 4.72% | 32    |
| Less than half of the usual | 12.68% | 86    |
| Almost zero | 56.78% | 385   |
| The number of nonmelanoma skin cancers you diagnosed (including by teleconsultations) during the pandemic was |       |       |
| The same as usual | 16.52% | 112   |
| A little bit lower than usual | 10.77% | 73    |
| Almost half of the usual | 8.26% | 56    |
| Less than half of the usual | 27.11% | 184   |
| Almost zero | 37.31% | 253   |
| During the pandemic, what was the main reason prompting patients to seek live dermatologic consultation? (more than 1 answer possible) |       |       |
| Tumors | 39.09% | 265   |
| Chronic skin diseases | 26.99% | 183   |
| Pruritic eruptions | 37.32% | 253   |
| Cosmetic problems | 8.55% | 58    |
| No predominant reason | 24.19% | 164   |
(21.98%) continued working on a daily basis, and 76/678 (11.21%) worked actively in COVID-19 dedicated departments. Among respondents, 188/678 dermatologists (27.73%) performed smart working performing visits through digital platforms and experienced telemedicine for the first time.

Overall, 214 dermatologists stated to have had contact with confirmed (87; 12.83%) or strongly suspected (124; 18.29%) COVID-19 patients. Of those 214 dermatologists, only 24 (3.54%) tested positive for SARS-CoV-2. Less than half of respondents (n = 297; 43.81%) reported the availability of sufficient personal protective equipment.

Regarding specific questions on dermatological manifestations of the virus, 1/6 of respondents stated to have visited COVID-19 positive (confirmed PCR on nasopharyngeal swab) patients with clinical manifestations (Table 3). Most clinical manifestations were observed in patients aged 1-20 years (n = 58, 31.44%), followed by 20- to 40-year age group (n = 54, 29.34%), 40-60 years (n = 42; 22.82%), and older than 60 (n = 30; 16.40%).

The most frequently noted clinical manifestations were acrodermatitis (n = 80; 21.50%), urticarial rash (n = 69; 18.54%), morbilliform skin rash (n = 53; 14.24%), purpuric manifestations (n = 49; 13.17%), followed by erythema polymorphous like rash (n = 37; 9.94%) and chickenpox like rash (n = 30; 8.06%) (Table 3). The skin lesions either appeared after the onset of systemic symptoms (n = 75; 35.89%) or were the only clinical manifestation in asymptomatic patients (n = 57; 27.27%) (Table 3). Most dermatologists reported that skin manifestations were mostly observed in asymptomatic (n = 89; 52.67%) or paucisymptomatic patients (n = 55; 32.54%).

The last part of the questionnaire (questions 21-24) focused on the implementation of telemedicine during the pandemic. Respondents also noted that the number of unofficial teleconsultations (eg, by mail, SMS, Skype, WhatsApp, messenger, etc.) that they were asked to do during the COVID-19 pandemic has increased by 83.33% (n = 565).

Remarkably, the number of melanomas diagnosed in these months was practically 0 for more than half (n = 385; 56.78%) of respondents. The reduction in diagnosis is also superimposable for nonmelanoma skin cancers (NMSCs) for which 253 dermatologists stated that the diagnosis was very close to 0, and 184 reported that the NMSC diagnosis was 50% less compared to previous months. Last, during the pandemic, the main reason for dermatological examinations were tumors considered by the patient to be suspicious, pruritic eruptions, followed by chronic skin diseases.

**Discussion**

The IDS promotes research and education of dermoscopy, a tool that is mostly implemented in early skin cancer diag-

### Table 3. Skin Findings in Patients Positive for SARS-CoV-2 Infection According to International Dermoscopy Society Survey Questions

| What kinds of skin manifestations did you see? (more than 1 answer possible) | %    | Count |
|---------------------------------------------------------------------------|------|-------|
| Morbilliform skin manifestation                                            | 14.24% | 53    |
| Erythema polymorphous like rash                                           | 9.94%  | 37    |
| Erythrodermic rash                                                        | 3.24%  | 12    |
| Chicken-pox like rash                                                     | 8.06%  | 30    |
| Urticarial rash                                                           | 18.54% | 69    |
| Purpuric manifestation                                                     | 13.17% | 49    |
| Acrodermatitis (chilblains)                                               | 21.50% | 80    |
| Herpes zoster virus reactivation                                           | 4.60%  | 17    |
| Psoriatic flare                                                           | 2.41%  | 9     |
| Atopic flare                                                              | 4.30%  | 16    |

**Skin manifestations (more than 1 answer possible)**

| Anticipated systemic symptoms                                              | 19.14% | 40    |
| Appeared after systemic symptoms                                           | 35.89% | 75    |
| Were the only ongoing manifestation of illness                             | 27.27% | 57    |
| Were a tardive manifestation of illness                                     | 17.70% | 37    |

**Skin manifestations were more commonly seen in (more than 1 answer possible)**

| Asymptomatic patients                                                      | 52.67% | 89    |
| Paucisymptomatic patients                                                  | 32.54% | 55    |
| Symptomatic patients                                                       | 14.79% | 25    |
nosis. In fact, the majority of IDS members work, at least to some extent, in skin cancer care. The fact that nearly 700 colleagues from 52 countries responded to the survey allows a proper view on the effective global impact of the COVID-19 pandemic on the routine work in dermatological care. Our data highlight a 75% reduction of the work and suggest that the COVID-19 health emergency had a particularly negative impact on dermatological care and practice [8]. This can be explained by the fact that most private and public clinics started to postpone all nonurgent visits and elective surgeries and medical procedures in order to reduce the risk of nosocomial transmissions. Although oncologic visits or surgery were guaranteed throughout the pandemic, our survey suggests that there was a significant decrease in daily clinical care of skin cancer patients. The survey revealed an alarming decrease of melanoma diagnosis during the pandemic. It is important to monitor whether this will induce an increase of thicker melanomas in the forthcoming months and years. This is especially relevant for fast-growing melanomas that have been estimated to invade the dermis at a rate of approximately 0.5 mm per month [9]. To overcome this challenge, it is paramount to provide timely care to patients, especially those who have a high risk of developing melanoma. Moreover, it would be essential, now more than ever, to increase patient and general practice physician education on early melanoma detection [10]. In this regard, the fight against skin cancer in the COVID-19 era should be largely based on 2 important tools, skin self-examination and teledermatology.

While there was a worrisome decrease in melanoma or NMSC diagnosis during the months of lockdown, 111/678 participants stated to have seen skin manifestations in confirmed or suspected COVID patients, obtaining real-life data quickly from all over the world about the skin manifestations of the SARS-CoV-2 virus. A majority of cutaneous manifestations of COVID-19 have been observed in asymptomatic or symptomatic patients, which means that dermatological clues may help clinicians suspect a COVID-19 infection when the symptoms cannot be associated with other causes. The urticarial and morbilliform rash were the most frequent signs followed by acrodermatitis (chilblains); the latter is not typical of the summer months and it should therefore be a warning to suspect COVID-19 infection, especially in the pediatric age. Other authors have also shown that this sign is more frequent in children [11].

Finally, our survey highlights that teledermatology consultations strongly increased during the outbreak. Data from this survey demonstrated that, since the beginning of the pandemic, worldwide outpatient activities have been reduced and online dermatological consulting has increased significantly. Online consultation can easily be used for dermatological diagnosis, as an initial triage of inflammatory pathologies or suspicious lesions can be identified via a video call with the aim of establishing the need to perform a dermoscopic examination to exclude or confirm a diagnosis.

During this time of unexpected and sudden changes and the need of social distancing, teledermatology has made it possible for many dermatologists to take care of patients remotely [12,13], and this tool is certain to be used increasingly in the immediate future. According to the recommendations from the European Academy of Dermatology and Venereology Task Forces, this is the time to organize and implement teledermatology services [14], in order to manage and care patients with skin lesions that are suspected of malignancy, non-melanoma skin cancer candidates to medical therapy and/or acute or chronic inflammatory cutaneous disorders from the safety of their homes. However, lesions suspected to be malignant should preferentially be managed via face-to-face visit [15].

This study has several limitations to underline: first of all, although the IDS community has almost 16,000 members, the response rate was 4.2% (678 responses/16,000 members) despite using a mailing list to reach as many members as possible. At first, it was decided to use 2 versions of the questionnaire, one in English and one in Russian; however, in order to avoid terminological bias and to ensure homogeneity of the data collected, only the questionnaires obtained in English were considered, considering that the official language of the IDS is English. Another limitation was that the terms “acrodermatitis” and “chilblains” were used synonymously because in the first weeks of the outbreak, when acral manifestations were observed in the pediatric population with the viral infection, there was still no direct correlation with either one of the 2 manifestations.

Conclusions

In conclusion, our study highlights that the outbreak had a negative impact on most dermatology services with a significant reduction in the time spent with patients with chronic disease and with a currently undefined risk of missed melanoma and NMSCs. Moreover, our study confirms earlier findings a wide range of skin manifestations associated with COVID, whereby especially the younger population develops skin lesions.

Following recommendations may help to close the gap of delayed healthcare for dermatologic patients in the next months: (i) improve accessibility to dermatologic care and the public health service system; (ii) implement prevention campaigns for the early detection of skin cancers; (iii) reactivate the follow-up of patients with melanocytic and nonmelanocytic tumors through reminders (calls, emails) to facilitate diagnostic and therapeutic adherence; and (iv) acrodermatitis, urticarial rash, and morbilliform skin rashes should lead to suspicion of COVID-19 infection.
Acknowledgments
The authors are thankful to all clinicians who completed the questionnaire.

References
1. Caldaria A, Conforti C, Di Meo N, et al. COVID-19 and SARS: Differences and similarities. Dermatol Ther. 2020;33(4):e13395. DOI: 10.1111/dth.13395.
2. Conforti C, Cannavò SP, Jafferany M, et al. Coronavirus disease 2019: facts and controversies. Dermatol Ther. 2020;33(4):e13366. DOI: 10.1111/dth.13366.
3. Abbott LM, Miller R, Janda M, et al. Practice guidelines for teledermatology in Australia 2020;61(3):e293-e302. Australas J Dermatol. DOI: 10.1111/ajd.13301. PMID: 32363572.
4. Villani A, Annunziata MC, Abategiovanni L, Fabbrocini G. Tele-dermatology for acne patients: how to reduce face-to-face visits during COVID-19. J Cosmet Dermatol. 2020;19(8):1828. DOI: 10.1111/jocd.13519. PMID: 32490578.
5. Piccolo V, Bassi A. Acral findings during the COVID-19 out-break: chilblain-like lesions should be preferred to acro-ischemic lesions. J Am Acad Dermatol. 2020;83(3):e231. DOI: 10.1016/j.jaad.2020.05.077. PMID: 32446827.
6. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34(5):e212-e213. DOI: 10.1111/jdv.16387
7. Conforti C, Zalaudek I, Giuffrida R, et al. “COVID-Mask”: an atypical livedoid manifestation of COVID-19 observed in a northern Italy hospital. Dermatol Ther. 2020;33(4):e13701. DOI: 10.1111/dth.13701
8. Gisondi P, Piaserico S, Conti A, Naldi L. Dermatologists and SARS-CoV-2: The impact of the pandemic on daily practice. J Eur Acad Dermatol Venereol. 2020;34(6):1196-1201. DOI: 10.1111/jdv.16515. PMID: 32320091.
9. Liu W, Dowling JP, Murray WK, et al. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol. 2006;142(12):1551–1558. DOI: 10.1001/archderm.142.12.1551.
10. Conforti C, Giuffrida R, Di Meo N, Zalaudek I. Management of advanced melanoma in the COVID-19 era. Dermatol Ther. 2020;33(4):e13444. DOI: 10.1111/dth.13444.
11. Piccolo V, Neri I, Filippeschi C, et al. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients. J Eur Acad Dermatol Venereol. 2020;34(7):e291-e293. DOI: 10.1111/jdv.16526.
12. Villani A, Scalvenzi M, Fabbrocini G. Teledermatology: a useful tool to fight COVID-19. J Dermatolog Treat. 2020;31(4):325. DOI: 10.1080/09546634.2020.1750557. PMID: 32238000.
13. Perkins S, Cohen JM, Nelson CA, Bunick CG. Teledermatology in the era of COVID-19: Experience of an academic department of dermatology. J Am Acad Dermatol. 2020;83(1):e43-e44. DOI: 10.1016/j.jaad.2020.04.048. PMID: 32305442.
14. EADV Task Force Recommendations. Accessed January 5, 2021. Available online at: https://eadv.org/covid-19/task-force
15. Conforti C, Giuffrida R, Vezzoni R, Resende FSS, di Meo N, Zalaudek I. Dermoscopy and the experienced clinicians. Int J Dermatol. 2020;59(1):16-22. DOI: 10.1111/jid.14512. PMID: 31222814.
16. Giuffrida R, Conforti C, Di Meo N, Deinlein T, Guida S, Zalaudek I. Use of noninvasive imaging in the management of skin cancer. Curr Opin Oncol. 2020;32(2):98-105. DOI: 10.1097/CCO.0000000000000611. PMID: 31850969.